2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Motor Activity
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammatory Breast Neoplasms
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Docetaxel
292
Prednisone
241
enzalutamide
195
Leuprolide
185
Radiotherapy
179
Abiraterone Acetate
170
Magnetic Resonance Spectroscopy
163
bicalutamide
141
Goserelin
138
Androgen Antagonists
121
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
108
Radiosurgery
108
apalutamide
93
abiraterone
83
gallium 68 PSMA-11
81
Specimen Handling
73
darolutamide
67
Surveys and Questionnaires
64
Gonadotropin-Releasing Hormone
63
Triptorelin Pamoate
58
Radiation
57
Biopsy
57
Brachytherapy
54
cabazitaxel
53
Standard of Care
51
Radiotherapy, Intensity-Modulated
51
Zoledronic Acid
50
pembrolizumab
49
luprolide acetate gel depot
49
Flutamide
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Clostridium perfringens epsilon-toxin
×
Clear all
NCT02435472
2025-04-11
ASX
University of California, San Francisco
Phase NA
Completed
104 enrolled